Project Grant R01AI184396
Award Date
6/9/25
Completion Date
5/31/30
Dollars Obligated
$813K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Houston, TX 77204, USA
Similar Awards
This Project Grant award for $147,656 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to uncover the three-dimensional ultrastructure, molecular architecture, and composition of the host-parasite interface of the Cryptosporidium pathogen. The research aims to reveal mechanisms of membrane remodeling and nutrient acquisition fundamental to intracellular parasitism, with the goal of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $242,250 to the University of Virginia to develop a vaccine against cryptosporidiosis, a common cause of diarrheal disease in Sub-Saharan Africa and Asia. The key objectives are to optimize the systemic and cellular immune responses to promising vaccine antigens, and to evaluate the protective efficacy of the optimal...
This federal Project Grant award for $773,053, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to advance the understanding of the cryptococcal cell wall composition and biosynthesis. The primary awardee, The Washington University, will conduct biochemical and genetic research to determine how the GGT2 glycosyltransferase affects the cryptococcal cell wall structure and integrity, as well...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $170,000.00 in funding to Prokaryotics Incorporated for a 2-year period from February 1, 2025 to January 31, 2027. The funding supports research to develop novel antifungal therapeutics that target the glycosylphosphatidylinositol (GPI) biosynthesis pathway in fungi. The key objectives are to conduct structural...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $402,860 to the University of Cincinnati to develop a molecular toolbox for the fungal pathogen Pneumocystis jirovecii. The primary goal is to establish a transformation system for this non-cultivable pathogen using CRISPR/Cas9 gene editing and plasmid-mediated approaches. During the initial R61 phase, the...
This $563,513 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the patterning, growth, and maturation of the cortical microtubules in the Toxoplasma parasite. The research aims to uncover the basic mechanisms by which this unicellular parasite, which causes diseases like toxoplasmosis, constructs its complex cytoskeletal framework. The findings...
This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover and develop new, more potent antifungal therapies for treating invasive fungal infections such as cryptococcosis, candidiasis, and aspergillosis. The funding will support the continued screening of chemical libraries to identify lead compounds that selectively inhibit the fungal ceramide synthase 1...
This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $1,373,790 grant supports research to develop a next generation of antimalarial compounds called ELQs (endochin-like quinolones) that can provide once-monthly oral protection against malaria. Key objectives include optimizing the structural features of the lead compound ELQ-596 to enhance its anti-plasmodial activity,...
The National Institute of Food and Agriculture (NIFA) within the U.S. Department of Agriculture awarded a $790,000 Project Grant to the University of Illinois under the Agriculture and Food Research Initiative (AFRI) competitive grants program (CFDA 10.310). The four-year project aims to develop novel drug therapies to treat Cryptosporidium parvum infections in livestock. C. parvum is a parasite that causes serious diarrheal illness in calves, lambs, and goat kids worldwide. Currently, there are...